feed,title,long_url,short_url
Benzinga,AIM ImmunoTech's Ampligen Shows Favorable Safety Profile In Early-Stage COVID-19 Study,https://benzinga.com/general/biotech/21/04/20520324/aim-immunotechs-ampligen-shows-favorable-safety-profile-in-early-stage-covid-19-study,https://j.mp/3rUINsJ
